Manufacturer of drug substance

Size: px
Start display at page:

Download "Manufacturer of drug substance"

Transcription

1 Original s and Biosimilars (marketing authorizations in the EU) Date: January ) Somatropin s ORIGINAL PRODUCTS: Authorization Genentech Genotropin Somatropin Pharmacia/ Pfizer E. coli Humatrope Somatropin Lilly Lilly E. coli Norditropin Somatropin Novo Nordisk Novo Nordisk E. coli Nutropinaq Somatropin Ipsen Genentech E. coli Somatropin Biopartners Somatropin BioPartners LG Life Sciences Saccharomyces cerevisiae Saizen Somatropin Merck Serono Merck Serono Mouse cells C127 Zomacton Somatropin Ferring Ferring E. coli Omnitrope Somatropin Sandoz Sandoz E. coli Genotropin, Somatropin

2 2) Filgrastim s ORIGINAL PRODUCTS: Neupogen Filgrastim Amgen Amgen E. coli Granocyte Lenograstim Chugai Pharma Chugai Pharma CHO cells Lonquex Lipegfilgrastim Teva Merckle Biotec E. coli Neulasta Pegfilgrastim Amgen Amgen E. coli Ristempa Pegfilgrastim Amgen Amgen E. coli The two products of Amgen (grey) are one product with two brand names, they are produced in one and the same manufacturing plant, are identical among each other and substitutable among each other. BIOSIMILARS: INN (Name of Filgrastim Filgrastim Hexal Sandoz E. coli Neupogen, Filgrastim Hexal Zarzio Filgrastim Sandoz Sandoz E. coli Neupogen, Filgrastim Ratiograstim Filgrastim ratiopharm SICOR Biotech E. coli Neupogen, Filgrastim Tevagrastim Filgrastim Teva SICOR Biotech E. coli Neupogen, Filgrastim Nivestim Filgrastim Hospira Hospira E. coli Neupogen, Filgrastim Grastofil Filgrastim Apotex Intas Pharmaceuticals E. coli Neupogen, Filgrastim Accofil Filgrastim Apotex Intas Pharmaceutical E. coli Neupogen, Filgrastim The products of Hexal and Sandoz are one biosimlar with two brand names (red); the products of Ratiopharm and Teva with three brand names (blue) are one biosimilar as this is the case for the products of Intas Pharmaceuticals (orange). Biosimilars with several brand names are produced in one and the same manufacturing plant of the generic producer, are therefore identical among each other and substitutable among each other. Seite 2/7

3 3) Epoetin s ORIGINAL PRODUCTS: Aranesp Darbepoetin alfa Amgen Amgen CHO cells Erypo Epoetin alfa Janssen-Cilag Johnson & CHO cells Johnson Neorecormon Epoetin beta Roche Roche CHO cells Mircera Methoxy-Poly- Roche Roche CHO cells ethylen-glycol- Epoetin beta Biopoin Epoetin theta Teva Merckle Biotec CHO cells Eporatio Epoetin theta Ratiopharm Merckle Biotec CHO cells The products of Teva and ratiopharm (orange) are one product with two brand names, they are produced in one and the same manufacturing plant, are identical among each other and substitutable among each other. BIOSIMILARS: Abseamed Epoetin alfa medice Lek; Rentschler CHO cells Erypo, Epoetin alfa Epoetin alfa Epoetin alfa Hexal Lek; Rentschler CHO cells Erypo, Epoetin alfa Hexal Binocrit Epoetin alfa Sandoz Lek; Rentschler CHO cells Erypo, Epoetin alfa Retacrit Epoetin zeta Hospira Norbitec CHO cells Erypo, Epoetin alfa Silapo Epoetin zeta Stada Norbitec CHO cells Erypo, Epoetin alfa The products of medice, Hexal and Sandoz are one biosimilar with three brand names (red); die products of Hospira and Stada are one biosimilar with two brand names (blue). Biosimilars with several brand names are produced in one and the same manufacturing plant of the generic producer, are therefore identically among each other and substitutable among each other. Seite 3/7

4 4) Follitropin alfa s ORIGINAL PRODUCT: of drug Gonal-f Follitropin alfa Merck Serono Merck Serono CHO cells BIOSIMILARS: Ovaleap Follitropin alfa Teva Merckle Biotec CHO cells Gonal-f, Follitropin alfa Bemfola Follitropin alfa Finox Biotech Polymun Scientific Immunbiologische Forschung CHO cells Gonal-f, Follitropin alfa Seite 4/7

5 5) Monoclonal Antibodies ORIGINAL PRODUCT: Remicade Infliximab Janssen Biologics of drug Janssen Biologics Mouse cells Inflectra Infliximab Hospira Celltrion Mouse cells Remicade, Infliximab Remsima Infliximab Celltrion Celltrion Mouse cells Remicade, Infliximab The products of Hospira and Celltrion (red) are one product with two brand names, they are produced in one and the same manufacturing plant, are identical among each other and substitutable among each other. Seite 5/7

6 6) Insulin glargine s ORIGINAL PRODUCT: of drug Lantus Insulin glargine Sanofi-Aventis Sanofi-Aventis E. coli of drug Abasaglar Insulin glargine Eli Lilly Lilly del Caribe, Eli Lilly and Company E. coli Lantus, Insulin glargin Seite 6/7

7 7) Fusion proteins ORIGINALPRÄPARAT: Enbrel Etanercept Pfizer Boehringer Ingelheim Pharma, Pfizer Ireland Pharmaceuticals CHO cells of drug Benepali Etanercept Samsung Bioepis Biogen Idec CHO cells Enbrel, Etanercept Seite 7/7

An Industry Perspective

An Industry Perspective AIPPI World IP Congress 2014 Workshop Pharma 2 Biosimilar pharmaceutical products An Industry Perspective September 16, 2014 Masahisa Yamaguchi, PhD Department Manager Intellectual Property Dept. Chugai

More information

November 2015. The Impact of Biosimilar Competition

November 2015. The Impact of Biosimilar Competition November 2015 The Impact of Competition Introduction This document sets out to describe the effects on price, volume and share following the arrival and presence of biosimilar competition in the European

More information

PRODUCT INN REFERENCE AUTHORIZATION Omnitrope

PRODUCT INN REFERENCE AUTHORIZATION Omnitrope PRODUCT INN REFERENCE AUTHORIZATION Omnitrope Genotropin 12/04/2006 somatropin Valtropin (W/D) Humatrope 24/04/2006 Abseamed Binocrit Epoetina alfa hexal Retacrit Silapo Biograstim Filgrastim ratiopharm

More information

BUY. Biosimilar play at attractive valuation BIOCON. Target Price: Rs 640. Key drivers(r&d value (Rs/sh) biosimilar pipeline)

BUY. Biosimilar play at attractive valuation BIOCON. Target Price: Rs 640. Key drivers(r&d value (Rs/sh) biosimilar pipeline) Biosimilar play at attractive valuation We highlight Biocon s base business and biosimilar pipeline are underappreciated by the Streetandthe company (ex-syngene^) trades at attractive valuation of17x FY17

More information

WHITE PAPER AN OUTLOOK ON US BIOSIMILAR COMPETITION

WHITE PAPER AN OUTLOOK ON US BIOSIMILAR COMPETITION WHITE PAPER AN OUTLOOK ON US BIOSIMILAR COMPETITION ANDREW FISCHER BOURGOIN, BETH NUSKEY APRIL 2013 2 AN OUTLOOK ON US BIOSIMILAR COMPETITION WHITE PAPER ANDREW BOURGOIN andrew.bourgoin@ thomsonreuters.com

More information

Lessons for the United States: Biosimilar Market Development Worldwide

Lessons for the United States: Biosimilar Market Development Worldwide Lessons for the United States: Biosimilar Market Development Worldwide Sumant Ramachandra, MD, PhD, MBA Senior Vice President, Chief Scientific Officer Hospira $67B+ of 2012 LMV is expected to face biosimilar

More information

Biological. Medicines. A Focus on Biosimilar. Medicines

Biological. Medicines. A Focus on Biosimilar. Medicines TM Biological Medicines TM EuropaBio is the voice of the European biotech Industry. It represents the interests of the industry towards the European institutions so that legislation encourages and enables

More information

3rd DVFA Life Science Conference 08 June 2010. Biosimilars. BIOCEUTICALS Arzneimittel AG. Epoetin zeta A case study

3rd DVFA Life Science Conference 08 June 2010. Biosimilars. BIOCEUTICALS Arzneimittel AG. Epoetin zeta A case study 3rd DVFA Life Science Conference 08 June 2010 Biosimilars BIOCEUTICALS Arzneimittel AG Epoetin zeta A case study Dr. Michael Mack Member of Executive Board BIOCEUTICALS Arzneimittel AG BIOCEUTICALS Arzneimittel

More information

A Comparison of US and EU Biosimilars Regimes

A Comparison of US and EU Biosimilars Regimes A Comparison of US and EU Biosimilars Regimes summary statement Economic barriers, along with regulatory complexity and uncertainty, are shaping the biosimilars industry into something entirely different

More information

No consensus concerning

No consensus concerning B i osi m i l ars MARKETS An Analysis of the US Biosimilars Development Pipeline and Likely Market Evolution by Ronald A. Rader No consensus concerning biosimilar-related terminology and definitions has

More information

GROWTH HORMONE THERAPY

GROWTH HORMONE THERAPY GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below including FDA-approved

More information

Clinical trial research agreement Agreed schedule 4 or 7 clause amendments

Clinical trial research agreement Agreed schedule 4 or 7 clause amendments Clinical trial research agreement Agreed schedule 4 or 7 clause amendments Medicines Australia and Medical Technology Association of Australia templates The sponsors in the table have agreed clauses for

More information

Biologics: Specific Drug Safety Challenges. Violetta B. Kyburz

Biologics: Specific Drug Safety Challenges. Violetta B. Kyburz Biologics: Specific Drug Safety Challenges Violetta B. Kyburz 2012 2013 2014 Biologics: Specific Drug Safety Challenges Topics for discussion Particular issues in the preclinical development of biologics

More information

Commercial Insight Osteoarthritis and Rheumatoid Arthritis

Commercial Insight Osteoarthritis and Rheumatoid Arthritis A Datamonitor In-Depth Analysis Commercial Insight Osteoarthritis and Rheumatoid Arthritis New Growth In A Mature Market Published: Jul-03 Product Code: DMHC1891 Why buy this analysis? Target current and

More information

Rx-360 An International Pharmaceutical Supply Chain Consortium

Rx-360 An International Pharmaceutical Supply Chain Consortium Rx-360 An International Pharmaceutical Supply Chain Consortium Overview Rx-360 and the Audit Sharing Program September 2011 Rx-360 Members (Continuously updated list at www.rx-360.org) Manufacturers (24)

More information

Ted Quiroz Director, Global Clinical Supply Chain Amgen Inc.

Ted Quiroz Director, Global Clinical Supply Chain Amgen Inc. Ted Quiroz Director, Global Clinical Supply Chain Amgen Inc. to serve patients Enbrel (etanercept) EPOGEN (Epoetin alfa) Aranesp (Darbepoetin alfa) Sensipar (cinacalcet HCl) Vectibix (panitumumab) We aspire

More information

CHEM-E4140 Selectivity 12. Pharma Business

CHEM-E4140 Selectivity 12. Pharma Business CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25

More information

Biosimilar By Name and Biosimilar By Nature

Biosimilar By Name and Biosimilar By Nature Biosimilar By Name and Biosimilar By Nature The use of unique non-proprietary names for biosimilars has broad implications for brand biologics and FDA s established regulation in the area. Why would the

More information

Shaping the biosimilars opportunity: A global perspective on the evolving biosimilars landscape

Shaping the biosimilars opportunity: A global perspective on the evolving biosimilars landscape Shaping the biosimilars opportunity: A global perspective on the evolving biosimilars landscape Shaping the biosimilars opportunity: A global perspective on the evolving biosimilars landscape After several

More information

Generic Biological Treatments and the Associated Cost Savings

Generic Biological Treatments and the Associated Cost Savings Robert J. Shapiro With Karan Singh and Megha Mukim February 2008 The Potential American Market for Generic Biological Treatments and the Associated Cost Savings TABLE OF CONTENTS Introduction...1 Biologics

More information

Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus)

Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus) A Datamonitor report Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus) Published: Oct 07 Product Code: DMTC2133 Providing you with: Identifies which technology vendors

More information

ehealthinsight Series: Online Patient Recruitment Strategies

ehealthinsight Series: Online Patient Recruitment Strategies A Datamonitor report ehealthinsight Series: Online Patient Recruitment Strategies Published: May-08 Product Code: Providing you with: Overview of benefits and drawbacks of online Analysis of online patient

More information

Letter to Shareholders

Letter to Shareholders Letter to Shareholders Robert A. Bradway, Chairman and Chief Executive Officer, Amgen Inc. Dear Shareholders, 2014 was an extraordinary year for Amgen financially, scientifically and organizationally.

More information

A World of Biomanufacturing: Shortages or Global Glut?

A World of Biomanufacturing: Shortages or Global Glut? A World of Biomanufacturing: Shortages or Global Glut? Howard L. Levine, Ph.D. BioProcess Technology Consultants, Inc. BioProcess International Conference Vienna, Austria May 19-20, 2010 Steady growth

More information

DPC AGGIORNATO AL 25/04/2011 PER SPECIALITA'

DPC AGGIORNATO AL 25/04/2011 PER SPECIALITA' DPC AGGIORNATO AL 2/04/20 PER SPECIALITA' 03682029 ABILIFY CPR. 0MG. N0AX2 ARIPIPRAZOLO 2 0368203 ABILIFY CPR. MG. N0AX2 ARIPIPRAZOLO 3 0368207 ABILIFY CPR. MG. N0AX2 ARIPIPRAZOLO 4 03682094 ABILIFY CPR.

More information

Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct

Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct Outcomes of Monitoring Committee Reviews Medicines Australia Code of Conduct 1 Medicines Australia ABN 23 126 990 001 Level 1, 16 Napier Close Deakin ACT 2600 Phone: 02 6122 8500 Fax: 02 6122 8555 Web:

More information

Annual Press Conference 2012. Business Year 2011

Annual Press Conference 2012. Business Year 2011 Business Year 2011 Highlights of the Business Year 2011 Andreas Barner Chairman of the Board of Managing Directors Corporate Board Division Pharma Research, Development and Medicine Value through Innovation

More information

Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity

Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity Brochure More information from http://www.researchandmarkets.com/reports/1383065/ Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity Description: Introduction Disease-modifying

More information

PlantForm Corporation

PlantForm Corporation PlantForm Corporation Professor J. Christopher Hall CSO PlantForm Corporation Canada s Top10 Winner Life Sciences 2008/9 Innovator of the Year Guelph, Canada, 2010 Opportunity The introduction of more

More information

PATIENT APPLICATION FORM INSTRUCTIONS

PATIENT APPLICATION FORM INSTRUCTIONS INSTRUCTIONS The Safety Net Foundation is a nonprofit patient assistance program that helps qualifying uninsured patients access Amgen medicines at no cost. To apply online, access program information

More information

Growth Hormone Deficiency

Growth Hormone Deficiency Growth Hormone Deficiency What is growth hormone deficiency? 1,2 Growth hormone deficiency is when your body doesn t make enough growth hormone. Growth hormone is one of many hormones made by the pituitary

More information

Challenges and Opportunities of Monoclonal Antibody Manufacturing in China

Challenges and Opportunities of Monoclonal Antibody Manufacturing in China BioPharma Antibody Therapeutics News Digest Challenges and Opportunities of Monoclonal Antibody Manufacturing in China Chris Chen Introduction About the Author: Dr. Chris Chen is currently Chief Operating

More information

ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Article. Biosimilars: Company Strategies to Capture Value from the Biologics Market

ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Article. Biosimilars: Company Strategies to Capture Value from the Biologics Market Pharmaceuticals 2012, 5, 1393-1408; doi:10.3390/ph5121393 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Article Biosimilars: Company Strategies to Capture Value from the

More information

PPRS 2014 analysis of growth in spend of branded medicines. DH Leading the nation s health and care

PPRS 2014 analysis of growth in spend of branded medicines. DH Leading the nation s health and care PPRS 2014 analysis of growth in spend of branded medicines March 2015 Executive Summary IMS Health data shows growth in spend in 2014 (compared to 2013) of 8.2% on branded medicines. This is higher than

More information

Biosimilars: Commercial Perspective

Biosimilars: Commercial Perspective February 4, 2014 Biosimilars: Commercial Perspective FTC Presentation, February 4 th 2014 Aaron (Ronny) Gal, Ph.D. (Senior Analyst) +1-212-756-4208 ronny.gal@bernstein.com Three topics Commercial rationale

More information

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013 Key Findings The global autoimmune market generated sales of $31.9bn in, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013.

More information

The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011

The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011 Brochure More information from http://www.researchandmarkets.com/reports/344881/ The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts

More information

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality 6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality March 24-25, 2015 Wyndham Philadelphia Historic District, Philadelphia, PA www.exlevents.com/gcp Sponsors

More information

Pharmaceutical sales in Canada have a 2.5 percent share of the global market, making th

Pharmaceutical sales in Canada have a 2.5 percent share of the global market, making th Industry Canada (/eic/site/icgc.nsf/eng/home) Home Industries and Business Canadian Life Science Industries Biopharmaceuticals and pharmaceuticals Pharmaceutical industry profile Life Science Industries

More information

Stakeholder Perspectives: Mild Cognitive Impairment and Dementia

Stakeholder Perspectives: Mild Cognitive Impairment and Dementia A Datamonitor In-Depth Analysis Stakeholder Perspectives: Mild Cognitive Impairment and Dementia Aricept in Race to Pioneer Unexplored Markets Published: Aug-03 Product Code: DMHC1924 Why buy this analysis?

More information

Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies

Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Biosimilar Monoclonal Antibodies in the Pipeline: Major Players and Strategies Fern Barkalow, Ph.D, Senior Analyst, Oncology Citeline One of the biggest challenges facing biosimilar drug developers is

More information

Pharma working capital performance highly variable

Pharma working capital performance highly variable April 2014 Pharma working capital performance highly variable 41 Billion in Excess Working Capital We last completed this survey in 2012. We expected that there would be a broad improvement across the

More information

Pharmaceutical industry

Pharmaceutical industry 8 th March 2016 Pharmaceutical industry 2015 Global ranking strategy decisive The annual company reporting season is always an exciting period. It is an ideal time to update our industry statistics and

More information

Multiple Sclerosis Treatments: World Market Outlook to 2011

Multiple Sclerosis Treatments: World Market Outlook to 2011 Brochure More information from http://www.researchandmarkets.com/reports/2860814/ Multiple Sclerosis Treatments: World Market Outlook to 2011 Description: Multiple sclerosis (MS) is a chronic demyelinating

More information

Biopharmaceutical Raw Materials throughout the Product Lifecycle

Biopharmaceutical Raw Materials throughout the Product Lifecycle February 27 March 2, 2012 Hilton San Diego Bayfront San Diego, CA Monday Tuesday Programming: IBC s 17th International Process & Analytical Assay Validation IBC s 8th International Outsourcing Manufacturing

More information

Commercial Perspectives: Multiple Sclerosis

Commercial Perspectives: Multiple Sclerosis A Datamonitor Report Commercial Perspectives: Multiple Sclerosis How to Find Opportunities in an Unremitting Market Published: Jun-04 Product Code: Providing you with: In-depth profiles of current market-leading

More information

Biologics and biosimilars. An overview

Biologics and biosimilars. An overview Biologics and biosimilars An overview Contents An introduction to biotechnology... 3 A brief history of medicine development... 4 What are biologic medicines?... 5 How are biologic medicines developed?...

More information

HISTORY OF DEVELOPMENT CURRENT INDICATORS DEVELOPMENT PROSPECTS

HISTORY OF DEVELOPMENT CURRENT INDICATORS DEVELOPMENT PROSPECTS HISTORY OF DEVELOPMENT CURRENT INDICATORS DEVELOPMENT PROSPECTS 1. COMPANY DESCRIPTION Biocad is a Russian full cycle biotechnological company. It deals with development, manufacture and promotion of original

More information

EU Clinical Trials Register

EU Clinical Trials Register EU Clinical Trials Register Sponsor Contact Information Abbott Laboratories Ltd Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire SL6 4XE UK Telephone number +44 1628 644475 euclinicaltrials@abbott.com

More information

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth Brochure More information from http://www.researchandmarkets.com/reports/2640803/ Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine

More information

Stakeholder Insight: Insulin Use in Type 2 Diabetes

Stakeholder Insight: Insulin Use in Type 2 Diabetes A Datamonitor Report Stakeholder Insight: Insulin Use in Type 2 Diabetes From Last Resort to Early Intervention Published: May-04 Product Code: DMHC1989 Providing you with: Analysis of Datamonitor s Diabetes

More information

Stakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm

Stakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm A Datamonitor report Stakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm Published: Sep-06 Product Code: Providing you with: Disease overview including epidemiology, physician

More information

Palliative Coverage Drug Benefit Supplement

Palliative Coverage Drug Benefit Supplement Palliative Coverage Drug Benefit Supplement Effective April 1, 2015 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)

More information

PATIENT ASSISTANCE PROGRAMS

PATIENT ASSISTANCE PROGRAMS PATIENT ASSISTANCE PROGRAMS Definitions SAP Class I Class II BC Cancer Agency Health Canada Special Access Program Reimbursed for active cancer or approved treatment or approved indication only Reimbursed

More information

Metastatic Breast Cancer - Pipeline Review, Q1 2011

Metastatic Breast Cancer - Pipeline Review, Q1 2011 Brochure More information from http://www.researchandmarkets.com/reports/1524592/ Metastatic Breast Cancer - Pipeline Review, Q1 2011 Description: Metastatic Breast Cancer - Pipeline Review, Q1 2011 Summary

More information

PHARMACEUTICAL INDUSTRY PROFILE

PHARMACEUTICAL INDUSTRY PROFILE PHARMACEUTICAL INDUSTRY PROFILE I. INDUSTRY BACKGROUND A. Industry Definition The U.S. pharmaceutical industry is defined by the Census Bureau as companies engaged in researching, developing, manufacturing,

More information

Global Monoclonal Antibodies Pipeline Insight 2015

Global Monoclonal Antibodies Pipeline Insight 2015 Brochure More information from http://www.researchandmarkets.com/reports/3113388/ Global Monoclonal Antibodies Pipeline Insight 2015 Description: Ever since the Nobel Prize was bestowed on the person who

More information

e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015

e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015 e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015 PHARMAPACK 2015 1 Mobile health x2 30 months 100 000 mapps Source: research2guidance, mhealth App Market Report 2013-2017

More information

WORLD PREVIEW 2014, OUTLOOK TO 2020

WORLD PREVIEW 2014, OUTLOOK TO 2020 WORLD PREVIEW 2014, OUTLOOK TO 2020 June 2014 Welcome to the EvaluatePharma World Preview 2014, Outlook to 2020 The seventh edition of EvaluatePharma s World Preview brings together many of our analyses

More information

Company Presentation June 2011 Biotest AG 0

Company Presentation June 2011 Biotest AG 0 Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and

More information

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Brochure More information from http://www.researchandmarkets.com/reports/3453273/ Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Description: About non-small cell lung cancer therapeutics

More information

Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies

Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies Brochure More information from http://www.researchandmarkets.com/reports/1504775/ Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies

More information

Briefing Paper on Biological and Biosimilar Medicines

Briefing Paper on Biological and Biosimilar Medicines Briefing Paper on Biological and Biosimilar Medicines Contents With our thanks IAPO would like to thank all those involved in planning this Toolkit and supporting its development. A full list of acknowledgements

More information

Uses of 2D gel electrophoresis in recombinant protein production. Kendrick Laboratories, Inc www.kendricklabs.com

Uses of 2D gel electrophoresis in recombinant protein production. Kendrick Laboratories, Inc www.kendricklabs.com Uses of 2D gel electrophoresis in recombinant protein production Kendrick Laboratories, Inc www.kendricklabs.com Recombinant proteins are biologics What is a Biologic? Biological products are those derived

More information

Patient Assistance PROGRAM PRIMER

Patient Assistance PROGRAM PRIMER Patient Assistance PROGRAM PRIMER The private benefits plan sponsor s guide to the patient assistance program Your guide to pharmaceutical manufacturers patient assistance programs for eligible plan members

More information

Total Compensation Measurement. Global TCM Participants. Turkey

Total Compensation Measurement. Global TCM Participants. Turkey Total Compensation Measurement 2008 Global TCM Participants Turkey Turkey 2008 TCM Participants Summary Information The table below lists key summary information on the 67 TCM participants for 2008. Measure

More information

Immune-response and adverse reactions: PRCA case example. Nicole Casadevall

Immune-response and adverse reactions: PRCA case example. Nicole Casadevall Immune-response and adverse reactions: PRCA case example Nicole Casadevall Recombinant human erythropoietin (rhuepo) 1985: EPO gene cloned 1986: first clinical trials in CKD 1988: rhepo is licensed for

More information

Meet Novartis Management

Meet Novartis Management Meet Novartis Management Joseph Jimenez, CEO and Harry Kirsch, CFO June 7-8, 0 Disclaimer This presentation contains forward-looking statements that can be identified by words such as momentum, progress,

More information

Brochure More information from http://www.researchandmarkets.com/reports/3292678/

Brochure More information from http://www.researchandmarkets.com/reports/3292678/ Brochure More information from http://www.researchandmarkets.com/reports/3292678/ Asia Pacific (India, China, Australia, South Korea & Others) Insulin Market (Rapid Acting, Short Acting, Pre-Mixed, Long

More information

Stakeholder Insight: Multiple Sclerosis Disease-modifying Efficacy and Side Effects Guide Treatment Choice

Stakeholder Insight: Multiple Sclerosis Disease-modifying Efficacy and Side Effects Guide Treatment Choice A Datamonitor report Stakeholder Insight: Multiple Sclerosis Disease-modifying Efficacy and Side Effects Guide Treatment Choice Published: Dec-06 Product Code: Providing you with: An overview of epidemiology,

More information

Mid-Year Report 2015

Mid-Year Report 2015 1 +2 Mid-Year Report 2015 1 +2 Half Year Report 2015 2 Table of Contents 3 Prefacing Remarks...4 Interim Financial Statements Consolidated Interim Financial Statements Management Report...8 Management

More information

KEEPING CLINICAL TRIALS IN AUSTRALIA

KEEPING CLINICAL TRIALS IN AUSTRALIA OCCASIONAL PAPER SERIES KEEPING CLINICAL TRIALS IN AUSTRALIA WHY ACTION IS NEEDED NOW OCCASIONAL PAPER SERIES > Medicines Australia is producing Occasional Papers to promote a contest of ideas, thought

More information

Anti-CD20 Monoclonal Antibodies - Global Strategic Business Report

Anti-CD20 Monoclonal Antibodies - Global Strategic Business Report Brochure More information from http://www.researchandmarkets.com/reports/1382330/ Anti-CD20 Monoclonal Antibodies - Global Strategic Business Report Description: This report analyzes the Global market

More information

(SAMPLE COPY, NOT FOR RESALE)

(SAMPLE COPY, NOT FOR RESALE) TriMark Publications June 2009 Volume: TMRTMA09-0601 THERAPEUTIC MONOCLONAL ANTIBODIES MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF

More information

Big Pharma s 2009-2013 Patent Cliff

Big Pharma s 2009-2013 Patent Cliff HONORS CAPSTONE IN BUSINESS Big Pharma s 2009-2013 Patent Cliff A Comparison of Company-Level Responses and Strategic Recommendations for Pfizer, Inc. and Eli Lilly and Company Benjamin Jardines, University

More information

Pharma working capital leaves room for improvement

Pharma working capital leaves room for improvement October 2012 Pharma working capital leaves room for improvement 50.7 Billion in Excess Working Capital Ten years ago it was not unusual to be asked why working capital mattered to a pharmaceutical company.

More information

Patient Satisfaction and Therapeutic Adherence Considerations of rhgh Dosing Devices

Patient Satisfaction and Therapeutic Adherence Considerations of rhgh Dosing Devices Patient Satisfaction and Therapeutic Adherence Considerations of rhgh Dosing Devices Robert Lipsy, PharmD Clinical Assistant Professor Department of Pharmacy Practice and Sciences University of Arizona

More information

In the largest and perhaps the most ambitious collaborative

In the largest and perhaps the most ambitious collaborative FEATURES THE BIRTH OF TRANSCELERATE BIOPHARMA, INC. Revolution in Clinical Research Partnerships by Dalvir Gill and Garry Neil In the largest and perhaps the most ambitious collaborative effort ever initiated

More information

REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Methotrexate in the 10MM (US, France, Germany,

More information

The power of creativity www.originbranding.com. Pharmaceutical Branding 2012

The power of creativity www.originbranding.com. Pharmaceutical Branding 2012 The power of creativity www.originbranding.com Pharmaceutical Branding 2012 We are an independent, boutique agency passionately focused on developing pharmaceutical brands. For over 15 years we have delivered

More information

Paul K. Wotton, Ph.D President and Chief Executive Officer May 2012 AMEX: AIS

Paul K. Wotton, Ph.D President and Chief Executive Officer May 2012 AMEX: AIS Paul K. Wotton, Ph.D President and Chief Executive Officer May 2012 AMEX: AIS Safe Harbor Statement This presentation may contain forward-looking statements which are made pursuant to the safe harbor provisions

More information

全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report

全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report /wepdwukltuyot 全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report 联 系 购 买 电 话 :010-82863480 公 司 名 称 : 佐 思 信 息 公 司 地 址 : 北 京 市 海 淀 区 苏 州 街 18 号 院 长 远 天

More information

Pharmaceutical Marketing Disclosures

Pharmaceutical Marketing Disclosures Pharmaceutical Marketing Disclosures July 1, 2007 June 30, 2008 Report of Vermont Attorney General William H. Sorrell April 2009 Prepared by staff of the Vermont Attorney General s Office: Wendy Morgan,

More information

Pipeline Insight: Schizophrenia Asenapine; A future market leader?

Pipeline Insight: Schizophrenia Asenapine; A future market leader? A Datamonitor report Pipeline Insight: Schizophrenia Asenapine; A future market leader? Published: Jul-06 Product Code: DMHC2186 Providing you with: Detailed pipeline analysis for key products in development

More information

M&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends

M&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends M&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends Symposium Life Science am Kapitalmarkt Frankfurt, 3. Juni 28 Global biotech industry Strong growth in most areas but Visible product

More information

OFFICE OF ATTORNEY GENERAL LAWRENCE G. WASDEN AVERAGE WHOLESALE PRICE LITIGATION REPORT AUGUST 2013

OFFICE OF ATTORNEY GENERAL LAWRENCE G. WASDEN AVERAGE WHOLESALE PRICE LITIGATION REPORT AUGUST 2013 Introduction OFFICE OF ATTORNEY GENERAL LAWRENCE G. WASDEN AVERAGE WHOLESALE PRICE LITIGATION REPORT AUGUST 2013 In 2007, Attorney General Wasden filed lawsuits against 33 pharmaceutical companies for

More information

Source: BIO, Factset, NASDAQ

Source: BIO, Factset, NASDAQ Inside The NBI A guide to performance drivers of the NASDAQ Biotech Index Introduction The NASDAQ Biotechnology Index (NBI) is referenced by investors, CEOs, and industry leaders around the world to take

More information

Triskel: a strategic consulting firm for biopharmaceutical companies

Triskel: a strategic consulting firm for biopharmaceutical companies BioStart : Manufacturing and operations in Biotech Strategic stakes and technology evolution in recombinant protein production APFL May 14 th, 2009 François LAWNY Triskel Integrated Services Geneva, Switzerland

More information

MRC Technology Centre for Therapeutics Discovery

MRC Technology Centre for Therapeutics Discovery MRC Technology Centre for Therapeutics Discovery fast-tracking discovery and development of novel drugs from academia Dr Duncan Young Business Development Manager UbiFrance Symposium, October 2012 established

More information

Current Regulatory thinking Around Biosimilars A Regulator s Perspective

Current Regulatory thinking Around Biosimilars A Regulator s Perspective Current Regulatory thinking Around Biosimilars A Regulator s Perspective Biologics and Biosimilars Symposium; 07 May, 2012 Dr. Elena Wolff-Holz Paul Ehrlich Institut Federal Agency for Vaccines and Biomedicines

More information

Accelerating Drug & Clinical Trial Approvals in China & East Asia

Accelerating Drug & Clinical Trial Approvals in China & East Asia 25 28 March 2014 The Westin Beijing Chaoyang, Accelerating Drug & Clinical Trial Approvals in & East Asia What s New in 2014? Key Regulatory Update from the National Institute for Food & Drug Control,

More information

Elisabeth B. Reynolds INDUSTRIAL PERFORMANCE CENTER MASSACHUSETTS INSTITUTE OF TECHNOLOGY WORKING PAPER SERIES MIT-IPC-11-001.

Elisabeth B. Reynolds INDUSTRIAL PERFORMANCE CENTER MASSACHUSETTS INSTITUTE OF TECHNOLOGY WORKING PAPER SERIES MIT-IPC-11-001. INDUSTRIAL PERFORMANCE CENTER MASSACHUSETTS INSTITUTE OF TECHNOLOGY WORKING PAPER SERIES Elisabeth B. Reynolds MIT-IPC-11-001 March 2011 292 Main Street, E38-104, Cambridge, MA 02139-4307 617-253-7522

More information

Ahighlight of the Pharma 50 ranking

Ahighlight of the Pharma 50 ranking www.pharmexec.com ELECTRONICALLY REPRINTED FROM JUNE 2014 Insight: The Accelerating Growth of Specialty Markets By Waseem Noor and Michael Kleinrock, IMS Photo: Thinkstock Ahighlight of the ranking over

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure

More information

General toxicity study designs

General toxicity study designs General toxicity study designs Jan Willem van der Laan Section on Safety of Medicines and Teratology Centre for Biological Medicines and Medical Technology National Institute for Public Health and the

More information

December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES

December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES by Dennis van Rooij with Tim van Tongeren EXECUTIVE SUMMARY More than half of pharma marketers don t or can t leverage

More information

Building innovative drug discovery alliances. Profitable. Growth Go

Building innovative drug discovery alliances. Profitable. Growth Go Building innovative drug discovery alliances Innovation n & Profitable Growth Go Evotec AG, H1 Presentation, 8 th August 2012 Forward-looking statements Information set forth in this presentation contains

More information

Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants

Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants Brochure More information from http://www.researchandmarkets.com/reports/1841621/ Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants Description: Introduction Beginning with

More information

BIOSIMILARS A COMPLETE DEVELOPMENT PLATFORM

BIOSIMILARS A COMPLETE DEVELOPMENT PLATFORM BIOSIMILARS A COMPLETE DEVELOPMENT PLATFORM FROM ORIGINATOR THROUGH COMPARABILITY TO MARKET STREAMLINE YOUR R&D, REGULATORY, ANALYTICAL, AND CLINICAL NEEDS WITH ONE PROVIDER The development pathway of

More information

Introduction to Drug Naming. Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs

Introduction to Drug Naming. Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs Introduction to Drug Naming Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs What s in a Name? International Nonproprietary Names (INN) Sponsored by World Health

More information